TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06448286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
Description: Undergo CEST MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study: NCT06233955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland mobilization technique
Description: is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
Study: NCT06452407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of elleFA smartphone application
Description: Participants will download the elleFA application on their smartphone. Through this application, the user will be prompted to complete a short modified Biberoglu and Behrman (B\&B) questionnaire and a longer EHP-30 questionnaire monthly, for a period of 6 months. Optionally, patients may complete an additional weekly summary of their mental health symptoms, pain localization, and other symptoms. Also optionally, they may record any daily symptoms, separated into categories from lifestyle to physical pain, objectified through a 6-point Likert scale.
Study: NCT05533151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
Study: NCT06439394

Intervention type: DRUG
Intervention: Optive MEGA-3 (OM3)
Description: Eye Drops
Study: NCT06497946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet prescription
Description: Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
Study: NCT06671392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202405
Description: 5/20mg, 1 tablet, Oral, Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202405, DWC202314
Description: 5/20mg + 1.5mg, 1 tablet, Oral, Once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWC202405, DWC202314P
Description: 5/20mg + 1.5mg, 1 tablet, Oral, Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202313, DWC202314
Description: 10/40mg + 1.5mg, 1 tablet, Oral, Once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWC202313, DWC202314P
Description: 10/40mg + 1.5mg, 1 tablet, Oral, Once a day
Study: NCT06673238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule
Study: NCT05826548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventioanl treatment group
Description: Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
Study: NCT06448286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT06511063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil/emtricitabine
Description: Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selzentry
Description: Participants will take Selzentry for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT05398003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the WAVEWRITER ALPHA ™ device
Description: The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)
Study: NCT03624400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT-I
Description: The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based psychoeducation
Description: Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
Study: NCT06370091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum of Xylitol
Description: After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum of sugar free
Description: After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gum of sugar
Description: After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Paraffin wax
Description: After each sample, the salivary pH level will be measured, and the amount of basal saliva will be weighed. This amount will be subtracted from the accumulated saliva at T4 to establish salivary flow
Study: NCT06218069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sasanlimab
Description: 6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sasanlimab
Description: 6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: non-ablative radiotherapy
Description: Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [89Zr]Zr-crefmirlimab berdoxam
Description: Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [89Zr]Zr-crefmirlimab berdoxam
Description: Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
Study: NCT05192122

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinue maintenance therapy SOC
Description: Continue maintenance therapy SOC

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinue maintenance therapy SOC
Description: Continue maintenance therapy SOC
Study: NCT05405114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDec - oral decitabine-tetrahydrouridine
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
Study: NCT04529044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT05405114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDec - oral decitabine-tetrahydrouridine
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDec - oral decitabine-tetrahydrouridine
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDec - oral decitabine-tetrahydrouridine
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU - Hydroxyurea
Description: Participants will get capsules daily (oral administration) according to local labelling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
Study: NCT05607797

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Epidemiological study
Description: Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidemiological study
Description: Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidemiological study
Description: Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)
Study: NCT05578690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups.
Study: NCT06157567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound Matrix
Description: Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
Study: NCT04529044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Receive 68Ga

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study: NCT04900363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Subjects receive AK112 intravenously.
Study: NCT06673238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule
Study: NCT04950543

Intervention type: BEHAVIORAL
Intervention: Meditation
Description: An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
Study: NCT04529044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05610644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric, isonitrogenous meals
Description: Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
Study: NCT06673238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule
Study: NCT05610644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric, isonitrogenous meals
Description: Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric, isonitrogenous meals
Description: Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric, isonitrogenous meals
Description: Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
Study: NCT05977998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IP (Intraperitoneal injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Given by IV (vein)
Study: NCT04794699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: IDE397 dosed orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: IDE397 dosed orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: IDE397 dosed orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: IDE397 dosed orally
Study: NCT05259709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr˗DFO˗REGN5054
Description: Administered by intravenous (IV) infusion during Part A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr˗DFO˗REGN5054
Description: Administered by intravenous (IV) infusion during Part A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered by IV infusion every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered by IV infusion every 3 weeks (Q3W).
Study: NCT05975047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIV001
Description: Part A- Participants will receive single dose of 280mg capsule on day 1 under fasting conditions; Part B- Participants will receive multiple doses of 280mg capsule from day 1 to day 14 under fasting conditions;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo across Part A and B of the study
Study: NCT06673238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule